BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Autor: Hussain, Maha H. A., Kocherginsky, Masha, Agarwal, Neeraj, Adra, Nabil, Zhang, Jingsong, Paller, Channing Judith, Picus, Joel, Reichert, Zachery R, Szmulewitz, Russell Zelig, Tagawa, Scott T., Kuzel, Timothy, Bazzi, Latifa, Daignault-Newton, Stephanie, Whang, Young E., Dreicer, Robert, Stephenson, Ryan D., Rettig, Matthew, Shevrin, Daniel, Chinnaiyan, Arul, Antonarakis, Emmanuel S.
Zdroj: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p19-19, 235p
Databáze: Supplemental Index